Clinical trial Recruiting at 18 sites Phase 3 Interventional Ages 18 and up

Comparing heart procedures for women with coronary artery disease

Official title: REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

Run by Weill Medical College of Cornell University · NCT06399692 · Data updated 2026-11-12

This study is testing which heart procedure, ballooning and stenting or open-heart surgery, works better for women with coronary artery disease to improve their health and quality of life.

More Coronary Artery Disease trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment600 (estimated)
SponsorWeill Medical College of Cornell University
Academic / other
Locations18 sites (Glendale, California and 17 other locations)
StatusRecruiting
StartedSeptember 16, 2024
Main results expectedMarch 15, 2033
Study endsJanuary 1, 2039
Registry record updatedSeptember 8, 2026
Trial IDNCT06399692 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18 and older with multivessel or left main coronary artery disease who are eligible for either CABG or PCI.

Probably not a fit

Patients with recent heart attacks, severe heart conditions, or those requiring other cardiac procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates two procedures for restoring blood flow in women with coronary artery disease: percutaneous coronary intervention (PCI), which involves ballooning and stenting blockages, and coronary artery bypass grafting (CABG), an open-heart surgery that uses healthy blood vessels to bypass blockages. It is a multicenter, randomized trial where participants will be followed for 5-10 years to assess survival rates and quality of life improvements. The study aims to provide insights into the best revascularization options for women, a group often underrepresented in cardiovascular research.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options and outcomes for women with coronary artery disease.

How similar studies have gone: Other studies have shown success in comparing these revascularization techniques, but this trial specifically focuses on women, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Female sex
2. Patient is at least 18 years old.
3. Multivessel or left main CAD is present for which revascularization is intended and for which there is equipoise between CABG and PCI according to local Heart Team assessment.
4. Ability to provide written informed consent and comply with all follow-up procedures, including QOL questionnaires.

Exclusion Criteria:

1. ST-segment elevation MI within 3 days
2. Cardiogenic shock
3. Prior PCI within 1 year or any in-stent restenosis with diameter stenosis ≥50% or any prior cardiac surgery
4. Planned hybrid revascularization (PCI after CABG or CABG after PCI)
5. Planned single vessel revascularization (other than isolated left main disease)
6. Need for any cardiac surgical or interventional procedure other than coronary revascularization at the present time or anticipated within 3 years, with the exception that surgical or interventional left atrial appendage ligation or occlusion and/or atrial fibrillation ablation may be performed at site discretion either during or subsequent to the index revascularization procedure
7. Pregnancy (women of child-bearing potential must have a negative pregnancy test within 1 week before randomization) or intent to become pregnant within 1 year after randomization
8. Unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 3 months if presentation with stable CAD or 6 months if presentation with a troponin-positive acute coronary syndrome
9. Current participation in another investigational drug or device study that has not reached its primary endpoint
10. Life-expectancy less than 3 years due to concomitant non-cardiac conditions
11. Any condition(s) are present that are likely to interfere with the study protocol procedures including medication adherence and follow-up through 10 years (e.g. mental disability, substance abuse, anticipated international relocation, etc.)

Where it's running

  • Adventist Health Glendale
    Glendale, California, United States
    Recruiting
  • Emory University
    Atlanta, Georgia, United States
    Recruiting
  • Ascension St. Vincent Cardiovascular Research Institute
    Carmel, Indiana, United States
    Recruiting
  • Baptist Health Lexington
    Lexington, Kentucky, United States
    Recruiting
  • Baptist Health Louisville
    Louisville, Kentucky, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
Show 12 more locations
  • Englewood Hospital
    Englewood, New Jersey, United States
    Recruiting
  • NewYork-Presbyterian Hospital - Queens
    Flushing, New York, United States
    Recruiting
  • Icahn School of Medicine - Mount Sinai Morningside
    New York, New York, United States
    Recruiting
  • Icahn School of Medicine - Mount Sinai Hospital
    New York, New York, United States
    Recruiting
  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
    New York, New York, United States
    Recruiting
  • Weill Cornell Medicine / NYPH
    New York, New York, United States
    Recruiting
  • Westchester Medical Center
    Valhalla, New York, United States
    Recruiting
  • Duke University
    Durham, North Carolina, United States
    Recruiting
  • Ohio State University
    Columbus, Ohio, United States
    Recruiting
  • Methodist Le Bonheur Healthcare
    Memphis, Tennessee, United States
    Recruiting
  • Ascension Saint Thomas Hospital
    Nashville, Tennessee, United States
    Recruiting
  • Baylor Scott and White
    Dallas, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Mario Gaudino, MD, PhD, MSCE, FEBCTS, FACC — Weill Medical College of Cornell University
  • Study coordinator: Mario Gaudino, MD, PhD, MSCE, FEBCTS, FACC
  • Email: mfg9004@med.cornell.edu
  • Phone: 212.746.1812

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.